Imidazoline Receptor System: The Past, the Present, and the Future

Area of Science:

• Pharmacology
• Neuroscience
• Endocrinology

Background:

• Imidazoline receptors (IRs) are a class of nonadrenergic binding sites, historically defined by their affinity for imidazoline-containing compounds.
• Despite initial definitions, endogenous ligands for IRs lack the imidazoline moiety and exhibit diverse chemical structures.
• Three subtypes (I1, I2, I3) have been proposed, with varying degrees of research progress.

Purpose of the Study:

• To review the progress in understanding I1 and I2 imidazoline receptors and their therapeutic potential.
• To highlight novel drug discovery efforts targeting these receptor subtypes for various disorders.

Main Methods:

• Review of existing literature on imidazoline receptor subtypes (I1, I2, I3).
• Analysis of preclinical and clinical data for novel I1 and I2 receptor agonists.
• Examination of the molecular associations and functional roles of imidazoline receptors.

Main Results:

• I1 receptor agonists, like moxonidine and rilmenidine, show antihypertensive effects with improved selectivity over older drugs.
• Newer I1 agonists (e.g., LNP599) exhibit high selectivity and potential for hypertension and metabolic syndrome.
• I2 receptor agonists (e.g., CR4056) demonstrate analgesic and neuroprotective effects, with a novel nonopioid analgesic in clinical trials.

Conclusions:

• Targeting I1 and I2 imidazoline receptors offers significant therapeutic potential for hypertension, metabolic syndrome, and chronic pain.
• Recent drug discovery efforts have yielded selective agonists with promising preclinical and clinical outcomes.
• Further research into the molecular identities and functions of imidazoline receptors could unlock new treatment strategies.